Market Spotlight: Myelofibrosis (MF)
Market Spotlight: Myelofibrosis (MF)
$1,318.00
Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Myelofibrosis (MF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 52,100 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 63,000 prevalent cases by 2030.
- Bristol Myers Squibb’s Inrebic, Incyte’s Jakafi, and CTI BioPharma’s Vonjo are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II, with only one drug in the NDA/BLA stage.
- Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.
- High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase II trial results for Xpovio, topline Phase III trial results for Reblozyl, Jakafi, navitoclax, imetelstat, pelabresib, INCB057643, INCB000928, and Vonjo, as well as an estimated PDUFA date for momelotinib.
- The overall likelihood of approval of a Phase I hematologic asset is 7.7%, and the average probability a drug advances from Phase III is 55.9%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.9 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for myelofibrosis have been in the early and mid-phases of development, with 87% of trials in Phase I–II, and only 13% in Phase III–IV.
- The US has a substantial lead in the number of myelofibrosis clinical trials globally. Italy leads the major European markets, while Israel and South Korea share the top spot in Asia.
- Novartis has the highest number of completed clinical trials for myelofibrosis, with 14 trials.
- Incyte leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Novartis.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Anemia
9 Splenomegaly
10 Curative treatment
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Momelotinib for Myelofibrosis (May 26, 2022)
25 Vonjo for Myelofibrosis (May 26, 2022)
26 Momelotinib for Myelofibrosis (January 25, 2022)
28 KEY UPCOMING EVENTS
29 KEY REGULATORY EVENTS
29 Sierra Fits In Momelotinib NDA Ahead Of GSK Takeover
29 CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval
30 PROBABILITY OF SUCCESS
31 LICENSING AND ASSET ACQUISITION DEALS
31 Another New Home For Momelotinib As GSK Buys Sierra
31 Active Biotech Teams With Oncode Institute For Myelofibrosis
31 Hansoh Licenses Cytopenia Candidate From Keros
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
39 BIBLIOGRAPHY
40 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of myelofibrosis, 2021–30
17 Figure 2: Overview of pipeline drugs for myelofibrosis in the US
17 Figure 3: Pipeline drugs for myelofibrosis, by company
18 Figure 4: Pipeline drugs for myelofibrosis, by drug type
18 Figure 5: Pipeline drugs for myelofibrosis, by classification
27 Figure 6: Momelotinib for Myelofibrosis (January 25, 2022): Phase III – MOMENTUM
28 Figure 7: Key upcoming events in myelofibrosis
30 Figure 8: Probability of success in the hematologic pipeline
33 Figure 9: Clinical trials in myelofibrosis
33 Figure 10: Top 10 drugs for clinical trials in myelofibrosis
34 Figure 11: Top 10 companies for clinical trials in myelofibrosis
34 Figure 12: Trial locations in myelofibrosis
35 Figure 13: Myelofibrosis trials status
36 Figure 14: Myelofibrosis trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of myelofibrosis, 2021–30
16 Table 2: Marketed drugs for myelofibrosis
19 Table 3: Pipeline drugs for myelofibrosis in the US
24 Table 4: Momelotinib for Myelofibrosis (May 26, 2022)
25 Table 5: Vonjo for Myelofibrosis (May 26, 2022)
26 Table 6: Momelotinib for Myelofibrosis (January 25, 2022)
32 Table 7: Historical global sales, by drug ($m), 2017–21
32 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Hypogonadism 
Sign up to the